Condition: Hypertrophic Cardiomyopathy · Sponsor: Viz.ai, Inc.
To describe the clinical, economic, and population characteristics of newly diagnosed, previously diagnosed, and suspected patients evaluated by Viz HCM. HCM is underdiagnosed in the community and AI algorithms have been developed as screening tools. However, it is not well understood how to best integrate AI screening tools and their potential impact.
This description comes directly from the study's public registry record.
Sloane Smith-Saunders, MBA, MPH · (754) 307-6336 · sloane.smith-saunders@viz.ai
Ethan Carter, BSN · (415) 409-9369 · ethan.carter@viz.ai
Always discuss trial participation with your own doctor first.
| Emory University | Atlanta, Georgia, United States | Not Yet Recruiting |
| North Shore University Health System | Evanston, Illinois, United States | Recruiting |
| Thomas Jefferson University | Philadelphia, Pennsylvania, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07103057